Thursday, October 1, 2020, 10:00 am - auditoire Maisin

Sohaib Mahri

Advanced Drug Delivery and Biomaterials, LDRI

Mechanisms of retention of PEGylated recombinant human deoxyribonuclease I (rhDNase) in the lungs

Mandatory registration for people attending in person : https://bit.ly/3mLfzex

Live event on Teams: https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzIzY2VkODgtOWZkMS00Mzc1LWIxZGUtODQ5MjY0NDM5YjNh%40thread.v2/0?context=%7b%22Tid%22%3a%227ab090d4-fa2e-4ecf-bc7c-4127b4d582ec%22%2c%22Oid%22%3a%22904d15ec-2b2a-4b50-bb75-6a1f392662a8%22%2c%22IsBroadcastMeeting%22%3atrue%7d

Promotor: Rita Vanbever

Co-Promotor: Cynthia Bosquillon

Related publications:

• Mahri, S. et al. , Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. Mahri, S., Rondon, A., Bosquillon, C., Vanbever, R. Submitted to Journal of Controlled Release (under revision).
• Mahri, S. et al, PEGylation decreases transport across lung epithelial cells and macrophage uptake of recombinant human deoxyribonuclease I. Hardy, E., De Keersmaecker, H., Braeckmans, K., De Smedt, S., Bosquillon, C., Vanbever, R. Submitted to International Journal of Pharmaceutics (under revision).
• Guichard, M.J, Wilms, T., Mahri S. et al, PEGylation of recombinant human deoxyribonuclease I provides a longacting version of the mucolytic for patients with cystic fibrosis. Submitted to Advanced Therapeutics (under revision).

Info: Rita.vanbever@uclouvain.be